**Article**

**Novel $[^{99m}TcN]^2+$ Labeled EGFR Inhibitors as Potential Radiotracers for Single Photon Emission Computed Tomography (SPECT) Tumor Imaging**

Mingxia Zhao, Hongyu Ning, Man Feng, Shilei Li, Jin Chang and Chuanmin Qi *

Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry, Beijing Normal University, Beijing 100875, China

* Author to whom correspondence should be addressed; E-Mail: qicmin@sohu.com; Fax: +86-10-5880-2075.

Received: 17 February 2014; in revised form: 21 April 2014 / Accepted: 21 April 2014 / Published: 29 April 2014

**Abstract:** The epidermal growth factor receptor (EGFR) is overexpressed in many cancers, including breast, ovarian, endometrial and non-small cell lung cancer. An EGFR-specific imaging agent could facilitate clinical evaluation of primary tumors or metastases. To achieve this goal, 4-(2-aminoethylamino)-6,7-dimethoxyquinazoline (ADMQ) was synthesized based on a 4-aminoquinazoline core and then conjugated with N-mercaptop- acetylglycine (MAG) and N-mercaptopacetyltriglycine (MAG3), respectively, to give compounds 1 and 2. The final complexes $[^{99m}TcN]-1$ and $[^{99m}TcN]-2$ were successfully obtained with radiochemical purities of >99% and >98% as measured by radio-HPLC. No decomposition of the two complexes at room temperature was observed over a period of 2 h. Their partition coefficients indicated they were hydrophilic and the electrophoresis results showed they were negatively charged. Biodistribution in tumor-bearing mice demonstrated that the two new complexes showed tumor accumulation, high tumor-tomuscle (T/M) ratios and fast clearance from blood and muscle. Between the two compounds, the $^{99m}$TcN-MAG3-ADMQ ($[^{99m}TcN]-2$) showed the better characteristics, with the tumor/muscle and tumor/blood ratios reached 2.11 and 1.90 at 60 min post-injection, 4.20 and 1.10 at 120 min post-injection, suggesting it could be a promising radiotracer for SPECT tumor imaging.
1. Introduction

Epidermal growth factor receptor (EGFR) is a member of the epidermal growth factor (EGF) family of tyrosine kinase receptors (which also includes ErbB2, ErbB3 and ErbB4). Ligand binding to the extracellular domain of the receptor results in the activation of the receptor [1,2]. The activated receptor can dimerize with other EGFRs followed by phosphorylation of tyrosine residues on the receptors. This active conformation makes it possible for TK domain of the receptors both to bind ATP and to transphosphorylate each other [3,4]. Receptor autophosphorylation on tyrosine residues both enhances the activity of kinases and provides docking sites for downstream signal transduction molecules that harbor SH2 or PTB domains. These interaction activate signal transduction pathways, which ultimately lead to multiple cellular processes, such as proliferation, differentiation, apoptosis, angiogenesis, cell adhesion and movement [5–7].

Correlation between EGFR overexpression and metastasis formation, therapy resistance, poor prognosis, and short survival has prompted the design and development of various anti-EGFR-targeted therapies [8–12]. Several quinazoline derivatives have been used as tyrosine kinase inhibitors targeting EGFR, such as gefitinib, erlotinib and lapatinib [13–16]. However, analysis of the expression of EGFR and the presence of mutations requires a tumor biopsy, which is not possible to get in all situations [17–20]. Thus, the ability to noninvasively quantitate EGFR content in tumors would aid in selecting patients who are likely to benefit from anti-EGFR-targeted therapy and in monitoring such treatment. Therefore, there has been a growing interest in the use of EGFR-TK inhibitors as radiotracers for molecular imaging of EGFR overexpressing tumors via nuclear medicine modalities such as SPCET and PET [21–25].

The $[^{99m}Tc]N^{2+}$ core exhibits a very high chemical stability and high affinity toward chelating ligands containing sulfur atoms which when present in the molecular structure of a radiopharmaceutical may dramatically affect its physical and biological behaviour [23,26]. Based on the good performance of quinazoline derivatives in anticancer applications, we have designed and synthesized 4-(2-aminoethylamino)-6,7-dimethoxyquinazoline (ADMQ, 8) by introducing a solubilizing basic ethylenediamine moiety at the 4-position of 4-chloro-6, 7-dimethoxyquinazoline (7) to link to the target molecules with MAG or MAG3, thus affording a new N3S type ligand. So far, the use of the ADMQ moiety 8 in the preparation of $^{99m}$Tc complexes as targeted agents for tumor imaging has not been reported. Herein, $^{99m}$TcN-MAG-ADMQ ($[^{99m}TcN]^{-1}$) and $^{99m}$TcN-MAG3-ADMQ ($[^{99m}TcN]^{-2}$) were designed and synthesized to evaluate the feasibility of the $^{99m}$Tc-labeled 4-aminoquinazoline derivatives as useful candidates for tumor imaging.

2. Results and Discussion

2.1. Chemistry

The synthesis of 4-(2-aminoethylamino)-6,7-dimethoxyquinazoline was carried out using the procedure shown in Scheme 1. A solution of compound 3 in AcOH was added to nitric acid solution
under stirring at 0–5 °C for 30 min and then at room temperature for 24 h to obtain 4. Compound 4 was hydrogenated with Pd/C in methanol at room temperature to obtain 5. Compound 5 was reacted with formamide at 165–170 °C under N2 to obtain 6, which was treated with thionyl chloride and DMF to get chloro derivative 7 and then 7 coupled with ethylenediamine in i-PrOH at 80 °C to obtain 8. The synthesis of compounds 9–12 is shown in Scheme 2. Compound 9 in which the thiol group was protected by trityl chloride in advance was reacted with N-hydroxysuccinimide (NHS) using dicyclohexylcarbodiimide (DCC) as condensation reagent to obtain the active ester 10. The active ester 10 was reacted with the amine group of glycine to provide the Tr-MAG (11).

**Scheme 1.** Synthesis of ADMQ.

Reagents and conditions: (a) AcOH, HNO3, 0–5 °C to rt, 24 h, 90%; (b) Pd/C, H2, rt, 8 h, 86%; (c) HCONH2, 165–170 °C, 6 h, 73%; (d) SOCl2, DMF, reflux, 4 h, 82%; (e) NH2CH2CH2NH2, i-PrOH, 80 °C, 4 h, 81%.

**Scheme 2.** Synthesis of Tr-MAG and Tr-MAG3.

Reagents and conditions: (a) NHS, DCC, anhydrous THF, −5 °C to rt, 10 h, 82%; (b) CH3CN, glycine, 50–60 °C, 2 h, 78%; (c) CH3CN, triglycine, 50–60 °C, 2 h, 71%.

Tr-MAG3 (12) was synthesized by the same procedure as 11, except using triglycine instead of glycine. Tr-MAG (11) was conjugated with compound 8 with DCC as condensation agent and 4-dimethylaminopyridine (DMAP) as nucleophilic agent to provide the compound 13. Tr-MAG3 (12) was conjugated with compound 8 under the same conditions to give compound 14. Next, the thiol groups were deprotected in trifluoroacetic acid (TFA) to obtain 1. Compound 2 was prepared using the same method as product 1.
2.2. Radiochemistry

2.2.1. Synthesis of $^{\text{99m}}$TcN-MAG-ADMQ and $^{\text{99m}}$TcN-MAG$_3$-ADMQ

Synthesis of the two compounds $^{\text{99m}}$TcN-1 and $^{\text{99m}}$TcN-2 was performed according to the procedure shown in Schemes 3 and 4.

**Scheme 3. Synthesis of $^{\text{99m}}$TcN-MAG-ADMQ.**

Reagents and conditions: (a) HOBt, DCC, Et$_3$N, anhydrous CH$_2$Cl$_2$, 0 °C to rt, 10 h, 61%; (b) Et$_3$SiH, TFA, rt, 5 min; (c) $^{\text{99m}}$Tc-SDC, SnCl$_2$, PDTA, rt to 100 °C, 30 min.

**Scheme 4. Synthesis of $^{\text{99m}}$TcN-MAG$_3$-ADMQ.**

Reagents and conditions: (a) HOBt, DCC, Et$_3$N, anhydrous CH$_2$Cl$_2$, 0 °C to rt, 10 h, 60%; (b) Et$_3$SiH, TFA, rt, 5 min; (c) $^{\text{99m}}$Tc-SDC, SnCl$_2$, PDTA, rt to 100 °C, 30 min.

For labeling, $^{\text{99m}}$TcN-1 was prepared through a SDH kit. $^{\text{99m}}$TcO$_4^-$ reacted with SDH in the presence of stannous chloride as reducing agent to form a technetium-99m nitrido intermediate. The $^{\text{99m}}$TcN$^{2+}$ is a suitable substrate for the substitution reaction with compound 1 at 100 °C for 15 min to give the final complex $^{\text{99m}}$TcN-1. The preparation of $^{\text{99m}}$TcN-2 was analogous to that for $^{\text{99m}}$TcN-1 given above, except that the ligand used was compound 2. Early experimental anionic compounds such as $^{\text{99m}}$TeO(MAG$_3$)$_{-}$, $^{\text{99m}}$TeO(MAG$_3$OMe)$_{-}$ and [ReO(MAG$_2$-pABAH)]$_{-}$ established the structure...
model using the N₂S ligand system [27,28]. It is reasonable to suppose that the structure of the two complexes in this paper might be similar to those that have been reported in the previous work for the same N₂S ligand system was employed to coordinate to ⁹⁹ᵐTc. The radiochemical purity of the two complexes was routinely checked by radio-HPLC. The HPLC patterns of [⁹⁹ᵐTcN]-1 and [⁹⁹ᵐTcN]-2 are shown in Figure 1. It was observed that the retention time of [⁹⁹ᵐTcN]²⁺ was 1.8 min, while those of [⁹⁹ᵐTcN]-1 and [⁹⁹ᵐTcN]-2 were found to be 4.4 min and 3.0 min, respectively. The mean radiochemical purity of the two products was over 90% immediately after the preparation.

Figure 1. Radio-HPLC chromatograms.

![Radio-HPLC chromatograms](image)

(A) ⁹⁹ᵐTcN²⁺, tᵣ = 1.8 min; (B) [⁹⁹ᵐTcN]-1, tᵣ = 4.4 min; (C) [⁹⁹ᵐTcN]-2, tᵣ = 3.0 min.

2.2.2. In Vitro Stability

The HPLC analysis results for the two complexes indicated that they were all stable in PBS after incubation for 2 h.

2.2.3. Paper Electrophoresis

Paper electrophoresis showed that about 90% of the initial activity remained in the positive electrode, indicating that they are negatively charged complexes.
2.2.4. Partition coefficients

As far as passive diffusion into tissues and cells is concerned, the lipophilicity of the molecule (generally denoted by log P) should be sufficiently high to allow penetration through the cell membrane. However, high log P values usually lead to slow clearance from blood, accumulation in metabolic tissue, and non-specific binding in tumors. The partition coefficients (log P) of [99mTcN]-1 and [99mTcN]-2 were measured according to the published method [29] (Table 1) and indicated that both complexes were hydrophilic. [99mTcN]-2 was less hydrophilic than [99mTcN]-1.

|   | [99mTcN]-1 | [99mTcN]-2 |
|---|------------|------------|
| log P | -1.81 ± 0.02 | -1.57 ± 0.01 |

2.2.5. Biological Evaluation

Mice were sacrificed and major organs such as brain, liver, lungs, kidneys, spleen, stomach and heart, as well as the tumors and blood, were isolated to evaluate the tissue distribution of the two complexes. The biodistribution results are summarized in Tables 2 and 3.

| Tissue                  | 30 min | 60 min | 120 min |
|-------------------------|--------|--------|---------|
| Heart                   | 0.27 ± 0.02 | 0.11 ± 0.01 | 0.05 ± 0.01 |
| Liver                   | 2.71 ± 0.16 | 1.01 ± 0.08 | 0.55 ± 0.11 |
| Spleen                  | 0.31 ± 0.03 | 0.15 ± 0.01 | 0.07 ± 0.02 |
| Lung                    | 1.36 ± 0.13 | 0.94 ± 0.06 | 0.44 ± 0.09 |
| Kidney                  | 2.42 ± 0.10 | 2.3 ± 0.07 | 1.35 ± 0.11 |
| Muscle                  | 0.27 ± 0.01 | 0.07 ± 0.01 | 0.06 ± 0.02 |
| Bone                    | 0.19 ± 0.02 | 0.16 ± 0.04 | 0.04 ± 0.01 |
| Large Intestine         | 0.71 ± 0.22 | 0.79 ± 0.12 | 0.51 ± 0.10 |
| Small Intestine         | 0.31 ± 0.01 | 0.25 ± 0.03 | 0.18 ± 0.03 |
| Stomach                 | 0.43 ± 0.05 | 0.04 ± 0.01 | 0.07 ± 0.03 |
| Brain                   | 0.04 ± 0.01 | 0.03 ± 0.02 | 0.01 ± 0.01 |
| Tumor                   | 0.35 ± 0.03 | 0.31 ± 0.04 | 0.07 ± 0.01 |
| Blood                   | 1.09 ± 0.11 | 0.82 ± 0.03 | 0.11 ± 0.04 |
| T/M ratio               | 1.29 ± 0.14 | 1.82 ± 0.33 | 1.17 ± 0.13 |
| T/B ratio               | 1.84 ± 0.07 | 1.94 ± 0.24 | 1.75 ± 0.16 |

T/M = tumor-to-muscle, T/B = tumor-to-blood; a All data are the mean percentage (n = 3) of the injected dose of [99mTcN]-1; per gram of tissue, ± the standard deviation of the mean.

There were apparent similarities in the biodistribution patterns of the two compounds that demonstrated tumor accumulation, high tumor-to-muscle (T/M) ratio, tumor-to-blood (T/B) ratio and rapid washout from blood. Early hepatic and renal activity reflected the two compounds were excreted through the hepatobiliary as well as the renal system. The clearance rate in the tumor was slower than in other tissues or organs with time, so the activity in the tumor exceeded that in most other tissue or organs. For [99mTcN]-1, the tumor-to-muscle (T/M) and tumor-to-blood (T/B) ratios reached 1.82
and 1.94 at 60 min, 1.17 and 1.75 at 120 min post-injection, respectively. For $[^{99m}\text{TcN}]-2$, the tumor-to-muscle (T/M) and tumor-to-blood (T/B) ratios reached 2.11 and 1.90 at 60 min, 4.20 and 1.10 at 120 min, respectively. Between them, $[^{99m}\text{TcN}]-2$ showed the better characteristics with the higher tumor/muscle ratio that reached to 4.2 at 120 min. The two compounds were hydrophilic so that they were unable to cross the blood brain barrier, thus making their brain uptake much lower. It is deemed worthwhile to modify the structure of ADMQ suitably to render it less hydrophilic to enhance the tumor uptake of its $^{99m}\text{Tc}$ labeled complex.

Table 3. Biodistribution of $[^{99m}\text{TcN}]-2$ in mice bearing S180 tumor (%ID/g) \(^b\).

| Tissue           | 30 min  | 60 min  | 120 min |
|------------------|---------|---------|---------|
| Heart            | 0.40 ± 0.05 | 0.12 ± 0.03 | 0.08 ± 0.01 |
| Liver            | 0.78 ± 0.09 | 0.79 ± 0.04 | 0.39 ± 0.05 |
| Spleen           | 0.16 ± 0.01 | 0.08 ± 0.02 | 0.05 ± 0.01 |
| Lung             | 0.50 ± 0.11 | 0.30 ± 0.08 | 0.14 ± 0.04 |
| Kidney           | 1.64 ± 0.15 | 1.97 ± 0.21 | 1.65 ± 0.16 |
| Muscle           | 0.25 ± 0.06 | 0.19 ± 0.02 | 0.05 ± 0.02 |
| Bone             | 0.55 ± 0.15 | 0.21 ± 0.06 | 0.20 ± 0.01 |
| Large Intestine  | 0.39 ± 0.17 | 0.51 ± 0.04 | 1.22 ± 0.24 |
| Small Intestine  | 0.99 ± 0.14 | 0.56 ± 0.09 | 0.20 ± 0.05 |
| Stomach          | 0.15 ± 0.03 | 0.14 ± 0.07 | 0.04 ± 0.02 |
| Brain            | 0.02 ± 0.01 | 0.01 ± 0.01 | 0.01 ± 0.005 |
| Tumor            | 0.21 ± 0.07 | 0.40 ± 0.05 | 0.21 ± 0.08 |
| Blood            | 0.96 ± 0.23 | 0.87 ± 0.16 | 0.13 ± 0.06 |
| T/M ratio        | 0.84 ± 0.09 | 2.11 ± 0.18 | 4.20 ± 0.25 |
| T/B ratio        | 0.38 ± 0.05 | 1.90 ± 0.16 | 1.10 ± 0.08 |

T/M = tumor-to-muscle, T/B = tumor-to-blood; \(^b\) All data are the mean percentage ($n = 3$) of the injected dose of $[^{99m}\text{TcN}]-2$; per gram of tissue, ± the standard deviation of the mean.

3. Experimental

3.1. General Information

Succinic dihydrazide (SDH) kit was obtained from Beijing Shihong Pharmaceutical Center, Beijing Normal University (Beijing, China). $^{99m}\text{Mo}/^{99m}\text{Tc}$ generator was obtained from the China Institute of Atomic Energy (CIAE) (Beijing, China). THF was refluxed over sodium/benzophenone and CH$_2$Cl$_2$ was refluxed over phosphorous CaH$_2$. Other solvents were purchased as anhydrous. $^1$H- and $^{13}$C-NMR spectra were recorded on a Bruker model (Bruker, Karlsruhe, Germany) spectrometer operating in DMSO-$d_6$ or CDCl$_3$ at 400 MHz and 100 MHz, respectively. $^1$H signals were reported in ppm. The IR spectra were recorded using KBr pellets in the 4,000-400 cm$^{-1}$ region on a Nicolet-AVATAR 360 FT-IR spectrometer (Nicolet-AVATAR, Belmont, MA, USA). ESI-MS spectra were obtained on Waters LCT Premier XE (Waters, Milford, MA, USA). HPLC analyses were performed on a Shimadzu SCL-10 AVP (Shimadzu, Kyoto, Japan) equipped with a Packard 500 TR series flow scintillation analyzer (Shimadzu) A C-18 reversed-phase Alltima column (5 μm, 150 mm × 4.6 mm) was used for radiochemical purity analysis.
3.2. Synthesis

The preparation of compounds 3–8 was carried out by the similar procedure described in [30,31] with some modifications. The synthesis of compounds 9–12 was carried out by the same procedure described in [32]. The preparation and the analysis data of the compounds are shown below.

**Ethyl 4,5-dimethoxy-2-nitrobenzoate (4).** A solution of ethyl 3,4-dimethoxybenzoate (6.0 g, 0.026 mol) in AcOH (23 mL) was added dropwise to nitric acid (6 mL, 65%) at 0–5 °C, and stirred at the same temperature for 30 min and then for 24 h at room temperature. Reaction progress was monitored by TLC and it was found to be complete after this time. The reaction mixture was poured onto ice/water to afford the yellow precipitate which was filtered and washed with ice water. The precipitate dried over P2O5 to afford the product 4 (5.91 g, yield 90.3%), m.p.: 78–79 °C.; IR (cm−1): ν 3451, 2983, 1722, 1609, 1389, 1361, 1294, 1219, 1016, 877; 1H-NMR (CDCl3) δ (ppm): 7.46 (1H, s, 6-H), 7.08 (1H, s, 3-H), 4.39 (2H, q, J = 7.08 Hz, -CH2), 3.98 (6H, s, -OCH3) 1.35 (3H, t, J = 7.16 Hz, -CH3). 13C-NMR (CDCl3) δ (ppm): 165.78 (C=O), 152.50 (5-C), 150.33 (4-C), 141.25 (2-C), 122.03 (1-C), 110.85 (6-C), 62.42 (-CH2), 56.61 (-OCH3), 56.57 (-OCH3), 13.74 (-CH3).

**Ethyl 2-amino-4,5-dimethoxybenzoate (5).** A solution of 4 (5.0 g, 0.020 mol) in methanol (30 mL) was hydrogenated with Pd/C (1.15 g) at room temperature. Reaction development was monitored by TLC and the reduction continued until no more hydrogen was consumed. The catalyst was filtered off and methanol removed to afford a brown precipitate which was filtered through a glass funnel and dried under reduced pressure (3.88 g, yield 85.5%), m.p.: 76–78 °C. IR (cm−1): ν 3489, 3375, 2978, 2829, 1680, 1591, 1516, 1398, 1300, 1157, 1029, 785, 592; 1H-NMR (CDCl3) δ (ppm): 7.32 (1H, s, 6-H), 6.14 (1H, s, 3-H), 5.57 (2H, br, -NH2), 4.32 (2H, q, J = 7.08 Hz, -CH2), 3.87 (3H, s, -OCH3), 3.87 (3H, s, -OCH3), 1.38 (3H, t, J = 7.12 Hz, -CH3). 13C-NMR (CDCl3) δ (ppm): 167.79 (C=O), 154.85 (4-C), 147.06 (2-C), 140.64 (5-C), 113.06 (6-C), 102.52 (1-C), 99.46 (3-C), 60.09 (-CH2), 56.55 (-OCH3), 55.76 (-OCH3), 14.50 (-CH3).

**6,7-Dimethoxyquinazoline-4-one (6).** A solution of 5 (2.5 g, 0.011 mol) in formamide (50 mL) was heated to 165–170 °C under N2 for 6 h. When TLC indicated the absence of starting material, the reaction mixture was cooled and the amber sticky precipitate was filtered using a sintered glass frit and dried on the air (1.90 g, yield 73.2%), m.p.: 295–296 °C. IR (cm−1): ν 3159, 3015, 2843, 2768, 1658, 1610, 1504, 1439, 1357, 1271, 1078, 877, 642; 1H-NMR (DMSO-d6) δ (ppm): 12.03 (1H, s, -NH), 7.99 (1H, s, 2-H), 7.42 (1H, s, 5-H), 7.11 (1H, s, 8-H), 3.88(3H, s, -OCH3), 3.85 (3H, s, -OCH3); 13C-NMR (DMSO-d6) δ (ppm): 159.99 (4-C), 154.43 (7-C), 148.53 (6-C), 144.84 (2-C) 143.77 (9-C), 115.58 (10-C), 108.00 (5-C), 104.93 (8-C), 55.88 (-OCH3), 55.66 (-OCH3).

**4-Chloro-6, 7-dimethoxyquinazoline (7).** A stirred mixture of 6 (2.0 g, 0.010 mol), thionyl chloride (30 mL) and N,N-dimethylformamide (0.6 mL) was heated under reflux for 4 h. The solvent was removed in vacuo to obtain the off-white crude product and the crude product was recrystallized in DMF to obtain the compound 7 (1.81g, yield 81.7%), m.p.: 178 °C. IR (cm−1): ν 3431, 1618, 1560, 1508, 1412, 1348, 1234, 1161, 968, 850, 698; 1H-NMR (DMSO-d6) δ (ppm): 8.88(1H, s, 2-H), 7.46(1H, s, 5-H), 7.41 (1H, s, 8-H), 4.00 (6H, s, -OCH3); 13C-NMR (DMSO-d6) δ (ppm): 158.82 (2-C),
155.05 (7-C), 149.34 (6-C), 145.86 (9-C), 138.85 (10-C), 114.73 (5-C), 105.52 (8-C), 104.11 (C-4), 56.16 (-OCH3), 55.94 (-OCH3).

4-(2-Aminoethylamino)-6,7-dimethoxyquinazoline (ADMQ, 8). To a solution of 7 (1.0 g, 4.5 mmol) in i-PrOH (30 mL) ethylenediamine (0.45 mL, 6.75 mmol) was added. The reaction mixture was heated to 80 °C and stirred for 4 h and then was quenched in ice water and filtered to afford the solid product 8 (0.9 g, yield 80.6%). IR (cm$^{-1}$): ν 3504, 3419, 3340, 2986, 2071, 1625, 1598, 1541, 1511, 1421, 1251, 843; 1H-NMR (DMSO-d$_6$) δ (ppm): 8.37 (1H, s, 2-H), 8.21 (1H, s, -NH), 7.67(1H, s, 5-H), 7.11(1H, s, 8-H), 3.90 (6H, s, -OCH3), 3.75 (2H, t, J = 5.96 Hz, -CH$_2$), 3.09 (2H, t, J = 5.96 Hz, -CH$_2$); 13C-NMR (DMSO-d$_6$) δ (ppm): 158.34 (7-C), 153.82 (4-C), 153.13 (2-C), 148.30 (6-C), 145.97 (9-C), 108.60 (10-C), 106.90 (8-C), 102.48 (5-C), 56.18 (-OCH3), 55.61 (-OCH3), 38.50 (2CH$_2$); MS (ESI): M = 248.1 (Found: 247.2); Anal. Calcd. for C$_{12}$H$_{16}$N$_4$O$_2$: C, 58.05; H, 6.50; N, 22.57%. Found: C, 57.88; H, 5.92; N, 22.62%.

Conjugation of Tr-MAG and ADMQ (Tr-MAG-ADMQ, 13). Triethylamine (0.13 mL, 0.9 mmol ) was added dropwise into a solution of 8 (148 mg, 0.6 mmol) in anhydrous dichloromethane (5 mL) and the mixture was stirred at room temperature for 5 min. After 11 and HOBt (90 mg, 0.66 mmol) were added to the mixture, DCC (138 mg, 0.66 mmol) in anhydrous dichloromethane (2 mL) was added dropwise to the solution at 0 °C. The mixture was stirred for 30 min at 0 °C and then overnight at room temperature to give a white precipitate which was removed by filtration. The organic phase was washed with saturated aqueous sodium bicarbonate, brine and dried over anhydrous sodium sulfate. After filtered and concentrated, the crude product was purified by column chromatography (petroleum ether/ethyl acetate = 1:3) to afford the desired compound 13 (yield: 60.5%). m.p. 188 °C; IR (cm$^{-1}$): ν 3358, 3326, 2928, 2850, 1625, 1574, 1535, 1307, 1247, 1088; 1H-NMR (DMSO-d$_6$) δ (ppm): 8.38 (1H, s, 2-H), 8.14 (1H, m, -NH), 8.09 (1H, m, -NH), 8.02–8.03 (1H, m, -NH), 7.54 (1H, s, 5-H), 7.24–7.26 (15H, m, Ar), 7.08 (1H, s, 8-H), 3.89 (3H, s, -OCH3), 3.86 (3H, s, -OCH3), 3.63(2H, m, -CH$_2$), 3.52–3.59 (4H, m, -CH$_2$), 2.86 (2H, s, -CH$_2$); 13C-NMR (DMSO-d$_6$) δ (ppm): 168.87 (C=O), 167.61 (C=O), 158.39 (7-C), 156.59 (4-C), 153.92 (2-C), 152.91 (6-C), 148.41 (9-C), 143.99 (3Ar-C), 129.03 (6Ar-C), 128.04 (6Ar-C), 126.77 (3Ar-C), 108.26 (10-C), 106.21 (8-C), 102.02 (5-C), 65.92 (-CH$_2$), 55.94 (-OCH3), 55.71 (-OCH3), 47.46 (-CH$_2$), 42.35 (-CH$_2$), 37.96 (-CH$_2$), 35.89 (-CH$_2$); MS (ESI): M = 621.2 (Found: 622.2); Anal. Calcd. for C$_{35}$H$_{35}$N$_5$O$_4$S: C, 67.61; H, 5.67; N, 11.26%. Found: C, 67.58; H, 5.72; N, 11.39%.

Conjugation of Tr-MAG$_3$ and ADMQ (Tr-MAG$_3$-ADMQ, 14). Compound 14 was using the same procedure as for the synthesis of 13 except using Tr-MAG$_3$ instead of Tr-MAG (yield: 60.1%). m.p.: 210 °C; IR (cm$^{-1}$): ν 3428, 3290, 1632, 1506, 1247, 1221, 704; 1H-NMR (DMSO-d$_6$) δ (ppm): 8.42 (1H, s, 2-H), 8.34 (1H, m, -NH), 8.19 (1H, m, -NH), 8.17 (1H, m, -NH), 8.11 (1H, m, -NH), 7.99 (1H, m, -NH), 7.62 (1H, s, 5-H), 7.24–7.26 (15H, m, Ar), 7.08 (1H, s, 8-H), 3.89 (6H, s, -OCH3), 3.58-3.88 (10H, m, -CH$_2$), 2.85 (2H, s, -CH$_2$); 13C-NMR (DMSO-d$_6$) δ (ppm): 169.13 (C=O), 169.09 (C=O), 167.77 (2C=O), 158.34 (4, 7-C), 153.85 (2-C), 153.10 (6-C), 148.36 (9-C), 143.93 (3Ar-C), 129.01 (6Ar-C), 128.03 (6Ar-C), 126.75 (3Ar-C), 108.35 (10-C), 106.47 (8-C), 102.01 (5-C), 65.92 (-CH$_2$), 55.92 (-OCH3), 55.64 (-OCH3), 42.31 (2CH$_2$), 42.05 (2CH$_2$), 38.02 (-CH$_2$), 35.85 (-CH$_2$); MS (ESI):
M = 735.3 (Found: 736.3); Anal. Calcd. for C_{39}H_{41}N_{7}O_{6}S: C, 63.66; H, 5.62; N, 13.32%. Found: C, 63.58; H, 5.71; N, 13.39%.

**Synthesis of $^{99m}\text{TcN-MAG-ADMQ}$ ([$^{99m}\text{TcN}$]-1)**

Compound 13 (5 mg) was treated with trifluoroacetic acid under cation trapping conditions (5% triethylsilane) at room temperature for 5 min and then the solvent was removed under a stream of nitrogen to give a residue which was neutralized with 0.1 M NaOH. The solution was extracted with dichloromethane for three times, and then the aqueous phase was placed under nitrogen protection. Saline (1 mL) containing $[^{99m}\text{TcO}_4]^{-}$ (15 MBq) was added to a kit containing stannous chloride dihydrate (0.05 mg), succinic dihydrazide (SDH, 5.0 mg) and propylenediamine tetraacetic acid (PDTA, 5.0 mg). The mixture was kept at room temperature for 15 min and then the MAG-ADMQ solution (1 mL) was added. The reaction mixture was allowed to stand for 15 min at 100 °C to give the final complex $^{99m}\text{TcN-MAG-ADMQ}$ ([$^{99m}\text{TcN}$]-1).

**Synthesis of $^{99m}\text{TcN-MAG3-ADMQ}$ ([$^{99m}\text{TcN}$]-2)**

[$^{99m}\text{TcN}$]-2 was prepared using the same method as [$^{99m}\text{TcN}$]-1 except using compound 14 instead of compound 13.

### 3.3. In Vitro Stability Study

Stability of the two complexes was studied using radio-HPLC analysis at different time intervals as soon as they were prepared. After the complexes were added to test tubes containing PBS solution (0.025 M, pH 7.4), the mixtures were incubated at 37 °C by shaking in a thermomixer. The radiochemical purity was measured at 30 min, 60 min and 120 min.

### 3.4. Radio-HPLC Analysis

The formation of the two complexes was routinely determined by Radio-HPLC. Water (solvent A) and acetonitrile (solvent B) were used for elution. For analysis of the product, the HPLC gradient system started with 100% A/0% B with a linear gradient to 0% A/100% B from 0 to 30 min. The flow rate was 1.0 mL/min. Sample (5 μL) was used for analysis. Recovery was determined by summing the total counts in all fractions and comparing them to the total injected activity.

### 3.5. Paper Electrophoresis

A 1 μL sample was spotted on a piece of Whatman 1 chromatography paper (length 15 cm) which was saturated with 0.05 M pH 7.4 phosphate buffer in an electrophoresis bath in advance. 150 V was applied for 2 h. The strip was then dried and divided into three segments. The distribution of radioactivity on each strip was determined.
3.6. Measurement of Partition Coefficients

The two complexes were each mixed with an equal volume of 1-octanol and phosphate buffer (0.025 M, pH 7.4) in a centrifuge tube. After vortexing at room temperature for 1 min, the mixture was centrifuged at 5,000 r/min for 5 min. The aliquot of each phase (0.1 mL) was pipetted and counted in a well-type NaI(Tl) detector and the process was repeated three times. The partition coefficient value was usually expressed as log P, where the partition coefficient, P, was calculated using the following equation:

\[ P = \frac{(\text{cps in octanol}-\text{cps in background})}{(\text{cps in buffer}-\text{cps in background})} \]

3.7. Biodistribution Study

Biodistribution studies of the two complexes were performed in Kunming female mice (18–22 g) bearing S 180 tumors, which grew to a leg diameter of 10–15 mm. \(^{99m}\text{TcN}-\text{MAG-ADMQ}, \) and \(^{99m}\text{TcN}-\text{MAG}_3-\text{ADMQ} \) (0.1 mL, 7.4 \times 10^5 Bq) were injected via the tail vein and the injected radioactivity was measured with a well-type NaI(Tl) detector, respectively. The mice were sacrificed at 30 min, 60 min and 120 min post-injection and the tumor, other organs of interest and blood were collected, weighed and measured for radioactivity. The results were expressed as the percent uptake of injected dose per gram of tissue (\%ID/g). All biodistribution studies were carried out in compliance with the national laws related to the conduct of animal experimentation.

4. Conclusions

In summary, 4-(2-aminoethylamino)-6,7-dimethoxyquinazoline (ADMQ) was successfully synthesized and conjugated with MAG and MAG\(_3\), respectively. The two new compounds were labeled with technetium-99m in high yields through a ligand exchange reaction, which was easily used for the preparation of a radiopharmaceutical through a freeze-dried kit formulation. Moreover, \([^{99m}\text{TcN}]-2\) demonstrates tumor accumulation, high tumor-to-muscle (T/M) ratios and rapid washout from blood. Thus, it appears of high interest to explore the \([^{99m}\text{TcN}]-2\) as a potential single photon emission computed tomography (SPECT) tumor imaging agent.

Acknowledgments

This work is supported by the National Natural Science Foundation of China (No. 21071022) and the Fundamental Research funds for the Central Universities. We especially thank Ms. Man Feng for her excellent work and kindly help for what we have done in the paper.

Author Contributions

M.X.Z. synthesized all ligands and complexes and participated in all steps of the research; H.Y.N. helped a lot in the complexes characterization; M.F. participated in all steps of the research; S.L.L. and J.C. participated on the writing of manuscript. C.M.Q. gave the concepts of work, interpreted the results and prepared the manuscript.
Conflicts of Interest

The authors declare no conflict of interest.

References

1. Hunter, T. Growth factors: The epidermal growth factor receptor gene and its product. *Nature* **1984**, *311*, 414–416.
2. Yarden, Y.; Schlessinger, J. Self-phosphorylation of epidermal growth factor receptor: Evidence for a model of intermolecular allosteric activation. *Biochemistry* **1987**, *26*, 1434–1442.
3. Iwashita, S.; Kobayashi, M. Signal transduction system for growth factor receptors associated with tyrosine kinase activity: Epidermal growth factor receptor signalling and its regulation. *Cell Signal.* **1992**, *4*, 123–132.
4. Voldborg, B.R.; Damstrup, L.; Spang-Thomsen, M.; Poulsen, H.S. Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. *Ann. Oncol.* **1997**, *8*, 1197–1206.
5. Olayioye, M.A.; Neve, R.M.; Lane, H.A.; Hynes, N.E. The ErbB signaling network: Receptor heterodimerization in development and cancer. *EMBO J.* **2000**, *19*, 3159–3167.
6. Prenzel, N.; Fischer, O.; Streit, S.; Hart, S.; Ullrich, A. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. *Endocr-Related Cancer* **2001**, *8*, 11–31.
7. Yarden, Y.; Sliwkowski, M.X. Untangling the ErbB signalling network. *Nat. Rev. Mol. Cell Biol.* **2001**, *2*, 127–137.
8. Levitzki, A. EGF receptor as a therapeutic target. *Lung Cancer* **2003**, *41*, 9–14.
9. Dissoki, S.; Eshet, R.; Billauer, H.; Mishani, E. Modified PEG-anilinoquinazoline derivatives as potential EGFR PET agents. *J. Label. Compound. Radiopharm.* **2009**, *52*, 41–52.
10. Mamot, C.; Drummond, D.C.; Greiser, U.; Hong, K.; Kirpotin, D.B.; Marks, J.D.; Park, J.W. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR-and EGFRvIII-overexpressing tumor cells. *Cancer Res.* **2003**, *63*, 3154–3161.
11. Shir, A.; Ogris, M.; Wagner, E.; Levitzki, A. EGF receptor-targeted synthetic double-stranded RNA eliminates glioblastoma, breast cancer, and adenocarcinoma tumors in mice. *PLoS Med.* **2005**, *3*, e6.
12. Levitzki, A.; Mishani, E. Tyrphostins and other tyrosine kinase inhibitors. *Annu. Rev. Biochem.* **2006**, *75*, 93–109.
13. Paez, J.G.; Jänne, P.A.; Lee, J.C.; Tracy, S.; Greulich, H.; Gabriel, S.; Herman, P.; Kaye, F.J.; Lindeman, N.; Boggon, T.J. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. *Science* **2004**, *304*, 1497–1500.
14. Lynch, T.J.; Bell, D.W.; Sordella, R.; Gurubhagavatula, S.; Okimoto, R.A.; Brannigan, B.W.; Harris, P.L.; Haserlat, S.M.; Supko, J.G.; Haluska, F.G. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer to gefitinib. *N. Engl. J. Med.* **2004**, *350*, 2129–2139.
15. Tsao, M.-S.; Sakurada, A.; Cutz, J.-C.; Zhu, C.-Q.; Kamel-Reid, S.; Squire, J.; Lorimer, I.; Zhang, T.; Liu, N.; Daneshmand, M. Erlotinib in lung cancer—molecular and clinical predictors of outcome. *N. Engl. J. Med.* 2005, 353, 133–144.

16. Pao, W.; Miller, V.; Zakowski, M.; Doherty, J.; Politi, K.; Sarkaria, I.; Singh, B.; Heelan, R.; Rusch, V.; Fulton, L. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. *Proc. Natl. Acad. Sci. USA* 2004, 101, 13306–13311.

17. Riely, G.J.; Politi, K.A.; Miller, V.A.; Pao, W. Update on epidermal growth factor receptor mutations in non–small cell lung cancer. *Clin. Cancer Res.* 2006, 12, 7232–7241.

18. Hoy, S.M.; Wagstaff, A.J. Panitumumab. *Drugs* 2006, 66, 2005–2014.

19. Berlin, J.; Posey, J.; Tchekmedyian, S.; Hu, E.; Chan, D.; Malik, I.; Yang, L.; Amado, R.G.; Hecht, J.R. Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer. *Clin. Colorectal Cancer* 2007, 6, 427–432.

20. Cohenuram, M.; Saif, M.W. Panitumumab the first fully human monoclonal antibody: From the bench to the clinic. *Anti-Cancer Drug.* 2007, 18, 7–15.

21. Kwak, E.L.; Sordella, R.; Bell, D.W.; Godin-Heymann, N.; Okimoto, R.A.; Brannigan, B.W.; Harris, P.L.; Driscoll, D.R.; Fidias, P.; Lynch, T.J. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. *Proc. Natl. Acad. Sci. USA* 2005, 102, 7665–7670.

22. Mishani, E.; Abourbeh, G.; Rozen, Y.; Jacobson, O.; Laky, D.; Ben David, I.; Levitzki, A.; Shaul, M. Novel carbon-11 labeled 4-dimethylamino-but-2-enolic acid [4-(phenylamino)-quinazoline-6-yl]-amides: Potential PET bioprobes for molecular imaging of EGFR-positive tumors. *Nucl. Med. Biol.* 2004, 31, 469–476.

23. Shaul, M.; Abourbeh, G.; Jacobson, O.; Rozen, Y.; Laky, D.; Levitzki, A.; Mishani, E. Novel iodine-124 labeled EGFR inhibitors as potential PET agents for molecular imaging in cancer. *Bioorg. Med. Chem.* 2004, 12, 3421–3429.

24. Bonasera, T.A.; Ortu, G.; Rozen, Y.; Krais, R.; Freedman, N.M.T.; Chisin, R.; Gazit, A.; Levitzki, A.; Mishani, E. Potential 18F-labeled biomarkers for epidermal growth factor receptor tyrosine kinase. *Nucl. Med. Biol.* 2001, 28, 359–374.

25. Neto, C.; Fernandes, C.; Oliveira, M.C.; Gano, L.; Mendes, F.; Kniess, T.; Santos, I. Radiohalogenated 4-anilinoquinazoline-based EGFR-TK inhibitors as potential cancer imaging agents. *Nucl. Med. Biol.* 2012, 39, 247–260.

26. Mang’era, K.O.; Vanbilloen, H.P.; Bellande, E.; Pasqualini, R.; Verbruggen, A.M. Influence of a $^{99m}$TcN core on the biological and physicochemical behavior of$^{99m}$Tc complexes of L, L-EC and L, L-ECD. *Nucl. Med. Biol.* 1996, 23, 987–993.

27. Grummon, G.; Rajagopalan, R.; Palenik, G.J.; Koziol, A.E.; Nosco, D.L. Synthesis, characterization and crystal structures of technetium (V)-Oxo complexes useful in nuclear medicine. 1. Complexes of mercaptoacetylglucylglycylglycine (MAG3) and its methyl ester derivative (MAG3OMe). *Inorg. Chem.* 1995, 34, 1764–1772.

28. Hansen, L.; Cini, R.; Taylor, A., Jr.; Marzilli, L.G. Rhenium (V) oxo complexes relevant to technetium renal imaging agents derived from mercaptoacetylglucylglycylaminobenzoic acid isomers. Structural and molecular mechanics studies. *Inorg. Chem.* 1992, 31, 2801–2808.
29. Purcell, W.P.; Bass, G.E.; Clayton, J.M. *Strategy of Drug Design: A Guide to Biological Activity*; Wiley: New York, NY, USA, 1973.

30. Pandey, A.; Volkots, D.L.; Seroogy, J.M.; Rose, J.W.; Yu, J.-C.; Lambing, J.L.; Hutchaleelaha, A.; Hollenbach, S.J.; Abe, K.; Giese, N.A. Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family. *J. Med. Chem.* **2002**, *45*, 3772–3793.

31. Kanter, J.; Pandey, A.; Robinson, J.; Scarborough, R.M. Preparation of substituted piperazinoquinazolines as kinase inhibitors. PCT Int. Appl. WO 2002036587, 2002.

32. Ding, R.; He, Y.; Xu, J.L.; Liu, H.; Wang, X.; Feng, M.; Qi, C.M.; Zhang, J.B. Synthesis and biological evaluation of pyrazolo[1,5-a]-pyrimidine-containing $^{99m}$Tc nitrido radiopharmaceuticals as imaging agents for tumors. *Molecules* **2010**, *15*, 8723–8733.

*Sample Availability*: Not available.

© 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).